{"id":"alks-37","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ALKS 37 works by activating GABA_A receptors, which are involved in regulating neuronal excitability and synaptic transmission. This mechanism is thought to contribute to its therapeutic effects.","oneSentence":"ALKS 37 is a dual GABA_A receptor agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:21:02.611Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-resistant schizophrenia"}]},"trialDetails":[{"nctId":"NCT01418092","phase":"PHASE2","title":"ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2011-09","conditions":"OIC","enrollment":91},{"nctId":"NCT01382797","phase":"PHASE2","title":"ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2011-08","conditions":"Opioid-induced Constipation","enrollment":157},{"nctId":"NCT01100151","phase":"PHASE2","title":"ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC)","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2010-04","conditions":"Opioid-induced Constipation","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ALKS 37","genericName":"ALKS 37","companyName":"Alkermes, Inc.","companyId":"alkermes-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ALKS 37 is a dual GABA_A receptor agonist. Used for Treatment-resistant schizophrenia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}